Von Willebrand Disease Market Report 2025

The von willebrand disease market size has grown strongly in recent years. It will grow from $1.74 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to several factors, including increased awareness of rare bleeding disorders, higher diagnosis rates of von Willebrand disease, growth in research funding for blood disorders, improved access to healthcare, and a rising use of prophylactic treatments in hemophilia care.

The von willebrand disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The projected growth during the forecast period can be attributed to factors such as the increasing development of gene therapies for bleeding disorders, rising investment in biotechnology research, a growing demand for non-invasive diagnostic techniques, the increasing use of digital health tools for disease monitoring, and the expansion of telemedicine services for rare diseases. Key trends for this period include advancements in gene therapy approaches, the integration of artificial intelligence in diagnostics, innovations in non-invasive diagnostic tools, the introduction of novel drug delivery systems, and the development of digital health platforms for patient education.

The increasing prevalence of bleeding disorders is expected to drive the growth of the von Willebrand disease market. Bleeding disorders refer to medical conditions that impair the body's ability to form blood clots, resulting in prolonged or excessive bleeding. The rise in diagnosed cases of bleeding disorders can be attributed to advancements in medical knowledge and diagnostic tools, which have enabled healthcare professionals to detect conditions that previously went unnoticed. Treatments for von Willebrand disease help patients by improving blood clotting, minimizing excessive bleeding, and enhancing their overall quality of life. For example, a report from the United Kingdom Haemophilia Centre Doctors’ Organization revealed that new registrations of Hemophilia A in the UK increased from 16 in 2021 to 19 in 2022. This growing awareness and diagnosis of bleeding disorders are contributing to the expansion of the von Willebrand disease market.

Key players in the von Willebrand disease market are focusing on developing innovative treatments, such as von Willebrand factor (VWF) concentrate, to improve treatment effectiveness, reduce bleeding episodes, and enhance patient outcomes. VWF concentrate is a medication used to treat and prevent bleeding in patients with von Willebrand disease, which is caused by a deficiency or dysfunction of the von Willebrand factor. For instance, in April 2024, Octapharma USA Inc., a US-based pharmaceutical company, announced that Wilate, a VWF concentrate, had been approved by the U.S. Food and Drug Administration (FDA). Wilate is a lyophilized powder solution for intravenous injection used for routine prophylaxis to reduce the frequency of bleeding episodes in both adults and children aged six and older. The FDA granted Wilate orphan drug designation, providing it with up to seven years of market exclusivity to encourage the development of treatments for rare diseases.

In January 2024, Takeda Pharmaceutical Company, based in Japan, acquired Shire plc. for $62 billion. This acquisition aims to strengthen Takeda's position in rare diseases, plasma-derived therapies, and hematology, including treatments for von Willebrand disease and other bleeding disorders. Shire plc, a UK-based biotechnology company, focuses on developing therapies for rare diseases, including von Willebrand disease.

Major players in the von willebrand disease market are Pfizer Inc., Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Mayo Clinic, CSL Behring (a subsidiary of CSL Limited), Cleveland Clinic, Grifols S.A., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., Biotest AG, Versiti Inc., Fortis Healthcare Limited, LFB S.A., Hualan Biological Engineering Inc., Bio Products Laboratory Ltd. (BPL), Octapharma AG, Sino Biological Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the von willebrand disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in von willebrand disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the von willebrand disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Von Willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein that plays a crucial role in blood clotting. The severity of the disorder depends on the amount and functionality of von Willebrand factor in the blood.

The main types of von Willebrand disease include type 1, type 2, and type 3. Type 1 is a mild form of the disorder, where individuals have lower-than-normal levels of von Willebrand factor, leading to difficulties in proper blood clotting. The drugs used to manage VWD include antihemophilic factor, coagulation factor VIII complex, von Willebrand factor, desmopressin acetate, and others, with severity levels ranging from mild to severe. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a variety of end-users, such as hospitals, specialty clinics, homecare providers, and others.

The von willebrand disease market research report is one of a series of new reports that provides von willebrand disease market statistics, including von willebrand disease industry global market size, regional shares, competitors with a von willebrand disease market share, detailed von willebrand disease market segments, market trends and opportunities, and any further data you may need to thrive in the von willebrand disease industry. This von willebrand disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The von willebrand disease market consists of sales of antifibrinolytic drugs, harmonal therapy, and clotting factor concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.